Neurologix Licenses Promising New Gene to Treat CNS Disorders

Neurologix, which through its subsidiary Neurologix Research, is engaged in the R&D of proprietary treatments for disorders of the brain and central nervous system (CNS) primarily using gene therapies, has licensed the humanin gene from Keio University in Tokyo as part of a strategic move to broaden its product portfolio.

The license agreement provides Neurologix with exclusive worldwide rights (excluding Japan) to develop and commercialize therapeutics to treat brain and other CNS disorders (excluding amyotrophic lateral sclerosis) using the humanin gene.